Downclassification of temporary mandibular condyle implants sought by Pfizer.
This article was originally published in The Gray Sheet
Executive Summary
MANDIBULAR CONDYLE TEMPORARY IMPLANT DOWNCLASSIFICATION SOUGHT BY PFIZER in a petition to FDA. The company argues that the devices pose less of a risk than permanent implants used to treat temporomandibular joint disorder because they usually remain in the patient only 6-12 months and have reduced load-bearing requirements compared to TMJ implants. The titanium temporary mandibular condyle implants sold by Pfizer's Howmedica Leibinger business are components of its Dynamic Bridging, Locking Screw, Luhr, Marx, 1st Generation Wurzburg, and 2nd Generation Wurzburg mandibular reconstruction systems.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.